TTRX - Turn Therapeutics Inc.

3.5
0.120   3.429%

Share volume: 13,857
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$3.38
0.12
0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
39%
Profitability 35%
Dept financing 40%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.37%
1 Month
-8.38%
3 Months
3.86%
6 Months
-50.00%
1 Year
-50.00%
2 Year
-50.00%
Key data
Stock price
$3.50
P/E Ratio 
0.00
DAY RANGE
$3.33 - $3.60
EPS 
-$0.07
52 WEEK RANGE
$2.57 - $26.50
52 WEEK CHANGE
-$50.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
29.445 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$25,228
AVERAGE 30 VOLUME 
$16,729
Company detail
CEO: Bradley Burnam
Region: US
Website: turntherapeutics.com/
Employees: 2
IPO year: 2025
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™, enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. Our principal executive offices are located in Westlake Village, CA.

Recent news